Reduced IL-35 levels are associated with increased platelet aggregation and activation in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Annals of Hematology

Volumn 94, Issue 5, 2015, Pages 837-845

  Zhang, Xiaohui ^a   Zhou, Yi ^a   Xu, Lanping ^a   Han, Wei ^a   Chen, Huan ^a   Chen, Yuhong ^a   Fu, Haixia ^a   Zhou, Shiyuan ^a   Zhao, Jingzhong ^a   Wang, Qianming ^a   Feng, Feier ^a   Zhu, Xiaolu ^a   Liu, Kaiyan ^a   Huang, Xiaojun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Acute graft versus host disease; Allogeneic hematopoietic stem cell transplantation; IL 35; Platelet aggregation

Indexed keywords

INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN;

ADOLESCENT; ADULT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; BLOOD; CHILD; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MIDDLE AGED; PHYSIOLOGY; PRESCHOOL CHILD; PROSPECTIVE STUDY; THROMBOCYTE AGGREGATION; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84930365697     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2278-7     Document Type: Article

References (45)

1. Copelan EA (2006) Hematopoietic stem-cell transplantation. N Engl J Med 354(17):1813–1826. doi:10.1056/NEJMra052638
2. Ferrara JL, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. Lancet 373(9674):1550–1561. doi:10.1016/S0140-6736(09)60237-3
3. Nakamura K, Amakawa R, Takebayashi M, Son Y, Miyaji M, Tajima K, Nakai K, Ito T, Matsumoto N, Zen K, Kishimoto Y, Fukuhara S (2005) IL-4-producing CD8(+) T cells may be an immunological hallmark of chronic GVHD. Bone Marrow Transplant 36(7):639–647. doi:10.1038/sj.bmt.1705107
4. Antin JH, Ferrara JL (1992) Cytokine dysregulation and acute graft-versus-host disease. Blood 80(12):2964–2968
5. Devergne O, Hummel M, Koeppen H, Le Beau MM, Nathanson EC, Kieff E, Birkenbach M (1996) A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 70(2):1143–1153
6. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, Liew FY (2007) IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37(11):3021–3029. doi:10.1002/eji.200737810
7. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450(7169):566–569. doi:10.1038/nature06306
8. Whitehead GS, Wilson RH, Nakano K, Burch LH, Nakano H, Cook DN (2012) IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J Allerg Clin Immunol 129(1):207–215. doi:10.1016/j.jaci.2011.08.009, e201-205
9. Graf L, Stern M (2012) Acute phase after haematopoietic stem cell transplantation: bleeding and thrombotic complications. Hamostaseologie 32(1):56–62. doi:10.5482/ha-1176
10. Wagner DD, Burger PC (2003) Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 23(12):2131–2137. doi:10.1161/01.ATV.0000095974.95122.EC
11. Burger PC, Wagner DD (2003) Platelet P-selectin facilitates atherosclerotic lesion development. Blood 101(7):2661–2666. doi:10.1182/blood-2002-07-2209
12. Yan SL, Russell J, Granger DN (2014) Platelet activation and platelet-leukocyte aggregation elicited in experimental colitis are mediated by interleukin-6. Inflamm Bowel Dis 20(2):353–362. doi:10.1097/01.MIB.0000440614.83703.84
13. Biedermann BC (2008) Vascular endothelium and graft-versus-host disease. Best Pract Res Clin Haematol 21(2):129–138. doi:10.1016/j.beha.2008.02.003
14. Piccin A, Murphy WG, Smith OP (2007) Circulating microparticles: pathophysiology and clinical implications. Blood Rev 21(3):157–171. doi:10.1016/j.blre.2006.09.001
15. Pihusch R, Hohnberg B, Salat C, Pihusch M, Hiller E, Kolb HJ (2002) Platelet flow cytometric findings in patients undergoing conditioning therapy for allogeneic hematopoietic stem cell transplantation. Ann Hematol 81(8):454–461. doi:10.1007/s00277-002-0494-z
16. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Wang JZ, Gao ZY, Zhang YC, Jiang Q, Shi HX, Lu DP (2006) Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 38(4):291–297. doi:10.1038/sj.bmt.1705445
17. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, Chen H, Liu DH, Gao ZY, Chen YH, Xu LP, Zhang YC, Ren HY, Li D, Liu KY (2006) Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107(8):3065–3073. doi:10.1182/blood-2005-05-2146
18. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18(4):295–304
19. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15(6):825–828
20. Zhang S, Yuan J, Yu M, Fan H, Guo ZQ, Yang R, Guo HP, Liao YH, Wang M (2012) IL-17A facilitates platelet function through the ERK2 signaling pathway in patients with acute coronary syndrome. PLoS One 7(7):e40641. doi:10.1371/journal.pone.0040641
21. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA (2011) Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 186(12):6661–6666. doi:10.4049/jimmunol.1100315
22. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA, Rehg JE, Jones ML, Ni HT, Artis D, Turk MJ, Vignali DA (2010) IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 11(12):1093–1101. doi:10.1038/ni.1952
23. Liu JQ, Liu Z, Zhang X, Shi Y, Talebian F, Carl JW Jr, Yu C, Shi FD, Whitacre CC, Trgovcich J, Bai XF (2012) Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis. J Immunol 188(7):3099–3106. doi:10.4049/jimmunol.1100106
24. Tirotta E, Duncker P, Oak J, Klaus S, Tsukamoto MR, Gov L, Lane TE (2013) Epstein-Barr virus-induced gene 3 negatively regulates neuroinflammation and T cell activation following coronavirus-induced encephalomyelitis. J Neuroimmunol 254(1–2):110–116. doi:10.1016/j.jneuroim.2012.10.005
25. Tong H, Miyazaki Y, Yamazaki M, Hara H, Waldmann H, Hori S, Yoshida H (2010) Exacerbation of delayed-type hypersensitivity responses in EBV-induced gene-3 (EBI-3)-deficient mice. Immunol Lett 128(2):108–115. doi:10.1016/j.imlet.2010.01.001
26. Liu Y, Cai Y, Dai L, Chen G, Ma X, Wang Y, Xu T, Jin S, Wu X, Qiu H, Tang X, Li C, Sun A, Wu D, Liu H (2013) The expression of Th17-associated cytokines in human acute graft-versus-host disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 19(10):1421–1429. doi:10.1016/j.bbmt.2013.06.013
27. Zhai Z, Sun Z, Li Q, Zhang A, Liu H, Xu J, Xu X, Geng L, Harris D, Hu S, Wang Y (2007) Correlation of the CD4 + CD25high T-regulatory cells in recipients and their corresponding donors to acute GVHD. Transplant Int Off J European Soc Organ Transplant 20(5):440–446. doi:10.1111/j.1432-2277.2007.00462.x
28. Taylor PA, Lees CJ, Blazar BR (2002) The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99(10):3493–3499
29. Zhao XY, Xu LL, Lu SY, Huang XJ (2011) IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation. Eur J Immunol 41(2):514–526. doi:10.1002/eji.201040793
30. Guo H, Wang W, Zhao N, He X, Zhu L, Jiang X (2013) Inhibiting cardiac allograft rejection with interleukin-35 therapy combined with decitabine treatment in mice. Transpl Immunol 29(1–4):99–104. doi:10.1016/j.trim.2013.10.001
31. Gorczynski R, Yu K, Chen Z (2014) Anti-CD200R2, anti-IL-9, anti-IL-35, or anti-TGF-beta abolishes increased graft survival and treg induction induced in cromolyn-treated CD200R1KO.CD200tg mice. Transplantation 97(1):39–46. doi:10.1097/TP.0b013e3182a8936a
32. Dumler JS, Beschorner WE, Farmer ER, Di Gennaro KA, Saral R, Santos GW (1989) Endothelial-cell injury in cutaneous acute graft-versus-host disease. Am J Pathol 135(6):1097–1103
33. Biedermann BC, Sahner S, Gregor M, Tsakiris DA, Jeanneret C, Pober JS, Gratwohl A (2002) Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 359(9323):2078–2083. doi:10.1016/S0140-6736(02)08907-9
34. Rand ML, Leung R, Packham MA (2003) Platelet function assays. Transfus Apher Sci 28(3):307–317. doi:10.1016/s1473-0502(03)00050-8
35. Jakubowski JA, Zhou C, Jurcevic S, Winters KJ, Lachno DR, Frelinger AL 3rd, Gupta N, Howard J, Payne CD, Mant TG (2014) A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thromb Res 133(2):190–195. doi:10.1016/j.thromres.2013.12.008
36. Davi G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357(24):2482–2494. doi:10.1056/NEJMra071014
37. Jennings LK (2009) Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 102(2):248–257. doi:10.1160/TH09-03-0192
38. Pinomaki A, Volin L, Joutsi-Korhonen L, Virtanen JO, Lemponen M, Ruutu T, Lassila R (2010) Early thrombin generation and impaired fibrinolysis after SCT associate with acute GVHD. Bone Marrow Transplant 45(4):730–737. doi:10.1038/bmt.2009.227
39. Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB (2008) The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 112(3):504–510. doi:10.1182/blood-2007-10-117051
40. Tuncer HH, Rana N, Milani C, Darko A, Al-Homsi SA (2012) Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. World J Gastroenterol WJG 18(16):1851–1860. doi:10.3748/wjg.v18.i16.1851
41. Tichelli A, Gratwohl A (2008) Vascular endothelium as ‘novel’ target of graft-versus-host disease. Best Pract Res Clin Haematol 21(2):139–148. doi:10.1016/j.beha.2008.02.002
42. Cheuk DK, Wang P, Lee TL, Chiang AK, Ha SY, Lau YL, Chan GC (2007) Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant 40(10):935–944. doi:10.1038/sj.bmt.1705835
43. Batts ED, Lazarus HM (2007) Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant 40(8):709–719. doi:10.1038/sj.bmt.1705758
44. Stavrou E, Lazarus HM (2010) Thrombotic microangiopathy in haematopoietic cell transplantation: an update. Mediterranean J Hematol Infect Dis 2(3):e2010033. doi:10.4084/MJHID.2010.033
45. Maione F, Cicala C, Liverani E, Mascolo N, Perretti M, D’Acquisto F (2011) IL-17A increases ADP-induced platelet aggregation. Biochem Biophys Res Commun 408(4):658–662. doi:10.1016/j.bbrc.2011.04.080